Marshall Wace North America’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Marshall Wace North America’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$368K	Buy	+60,215	New	+$375K	﹤0.01%	1197
2021 Q2	–	Sell	-19,262	Closed	-$172K	–	1948
2021 Q1	$172K	Buy	+19,262	New	+$221K	﹤0.01%	1422
2020 Q4	–	Sell	-97,531	Closed	-$1.01M	–	1703
2020 Q3	$1.01M	Sell	97,531 -79,613	-45%	-$976K	0.01%	800
2020 Q2	$2.33M	Buy	+177,144	New	+$1.84M	0.02%	549
2019 Q1	–	Sell	-5,610	Closed	-$64K	–	2033
2018 Q4	$64K	Buy	+5,610	New	+$88K	﹤0.01%	1190

Other funds holding FLXN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace North America's FLXN Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Flexion Therapeutics, Inc. (FLXN) in Q3 2021: 60,215 shares worth $368K. The stake represents ﹤0.01% of the portfolio and ranks #1197 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in FLXN as recently as Q1 2021.

Marshall Wace North America first reported a position in FLXN in Q4 2018 and has held it in 5 quarters since. The position peaked at $2.33M in Q2 2020. 145 funds tracked by Wall St. Rank hold FLXN as of Q3 2021.

Marshall Wace North America held 60,215 shares of Flexion Therapeutics, Inc. worth $368K as of Q3 2021.
Flexion Therapeutics, Inc. was a new Marshall Wace North America position in Q3 2021.
Flexion Therapeutics, Inc. made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1197 holding.
Marshall Wace North America first reported a position in Flexion Therapeutics, Inc. in Q4 2018 and has held it in 5 quarters since.
Marshall Wace North America's Flexion Therapeutics, Inc. position peaked at $2.33M in Q2 2020.
145 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.